WO2019066131A1 - 자궁 경부용 키토산 기반의 지혈부재 및 이의 제조방법 - Google Patents
자궁 경부용 키토산 기반의 지혈부재 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2019066131A1 WO2019066131A1 PCT/KR2017/012825 KR2017012825W WO2019066131A1 WO 2019066131 A1 WO2019066131 A1 WO 2019066131A1 KR 2017012825 W KR2017012825 W KR 2017012825W WO 2019066131 A1 WO2019066131 A1 WO 2019066131A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cmcs
- chitosan
- hemostasis
- hemostatic
- bundle
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/36—Surgical swabs, e.g. for absorbency or packing body cavities during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15577—Apparatus or processes for manufacturing
- A61F13/15699—Forming webs by bringing together several webs, e.g. by laminating or folding several webs, with or without additional treatment of the webs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15577—Apparatus or processes for manufacturing
- A61F13/15707—Mechanical treatment, e.g. notching, twisting, compressing, shaping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/44—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators with radio-opaque material or signalling means for residual material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/54—Radio-opaque materials
Definitions
- the present invention relates to a hemostatic member using chitosan having excellent hemostatic function, and more particularly, to a chitosan-based hemostatic member for cervical chitosan which enables effective hemostasis against a lesion at the time of cervical tissue examination or surgery, .
- Korean Patent No. 10-1700107 entitled “ Chitosan-based hemostatic dressing material and its manufacturing method, " filed by the present applicant with the prior art relating to the present invention, is known.
- the chitosan-based hemostatic dressing is composed of a chitosan dressing material composed of a 100% chitosan material and having a predetermined size and shape and is applied to a wound or a surgical site of a human body and is involved in hemostasis and recovery of a wound or a surgical site,
- the chitosan dressing material comprises a chitosan dressing material which is bonded to at least one surface of the chitosan dressing material and which is used for preventing detachment of fibers and for maintaining the shape of the chitosan dressing material.
- Ray-sensitive material so as to make it possible to identify the X-ray sensitive substance.
- Chitosan is a natural polysaccharide known to have a hemostatic effect and antibacterial and antiviral effect. It is a polysaccharide that deacetylates chitin contained in cell walls of crabs, shrimp bark, squid bones, fungi and bacteria It has been used in various industrial fields since the mid-1980s.
- the chitosan is mainly used for wastewater treatment such as coagulant, heavy metal adsorbent, dye waste water purifying agent, soil improvement agent, insecticide, plant antiviral agent and agricultural chemicals.
- wastewater treatment such as coagulant, heavy metal adsorbent, dye waste water purifying agent, soil improvement agent, insecticide, plant antiviral agent and agricultural chemicals.
- It is expanding its scope to include applications, health and hygiene applications, cosmetics, textile, and pharmaceutical applications.
- chitosan has been used as a wound healing agent, an artificial skin, a coloring material, a blood coagulant, an artificial kidney membrane, a biodegradable surgical suture, and an antibacterial material,
- chitosan Through the useful function of chitosan, it is intended to provide a hemostatic dressing material which can be used universally in the prior art.
- the conventional technique can be used as a dressing material for hemostasis of the external skin of the body.
- general dressing materials are limited to hemostasis .
- What is noticed in the present invention is to enable effective hemostasis against the lesion that occurs when a biopsy is performed for surgery or diagnosis of cervical cancer of a woman.
- a hemostatic member capable of achieving an effective hemostatic effect on the affected part, rather than a gauze-like shape that can be used commonly as in the prior art.
- the present invention provides a hemostatic member based on chitosan for cervix, which can effectively perform hemostasis against the affected part when hemostasis is required for the cervix due to surgery or biopsy.
- the chitosan-based hemostatic member according to the present invention for achieving the above-mentioned object is a hemostatic member used for insertion of a chitosan-based nonwoven fabric into the affected part at the time of uterine biopsy or surgery, And a hemostasis bundle having a nip portion is formed by binding with a thread, and the X-ray sensitive material is included in the thread.
- CMCS coating layer coated with CMCS is formed on the outer surface of the hemostasis bundle.
- CMCS sponge is wrapped over the CMCS coating layer.
- the CMCS sponge is wrapped around the outer surface of the hemostasis bundle.
- the CMCS sponge has a thickness in the range of 2 to 10 mm.
- a chitosan-based hemostatic member for cervical chitosan comprising a hemostatic bundle having a nip portion by tying an upper end of the chitosan nonwoven fabric to form a round shape,
- the general nonwoven fabric or the chitosan nonwoven fabric is linearly joined to both the left and right sides to form a peripheral pressing portion and a thread including an X-ray sensitive substance is connected to the peripheral pressing portion.
- the thread connected to the peripheral squeezing portion extends through the peripheral squeeze portion by one strand from the inside of the hemostatic trousers.
- a method of preparing a chitosan-based hemostatic member for cervical cancer comprising the steps of: preparing a chitosan nonwoven fabric comprising chitosan fibers; Collecting the chitosan nonwoven fabric in a state of laminating a plurality of chitosan nonwoven fabrics, and collecting edges of the chitosan nonwoven fabric so as to form a nodule, and binding the chitosan nonwoven fabric with a thread including an x-ray sensitive material to form a hemostatic hemostasis bundle in a round shape.
- the CMCS sponge forming step includes: a hemostasis holding step for seating a hemostasis bundle on which the CMCS coating layer is formed; Injecting the CMCS solution into the mold; Drying the CMCS solution by integrating the CMCS solution with the hemostasis bundle by lyophilization; And a heat treatment step of applying heat to the lyophilized body formed by the lyophilization so as to perform heat treatment.
- the pre-freezing step is performed prior to the lyophilization step, wherein the mold is stabilized at 0 to -5 DEG C for 1 to 2 hours and then immersed in ethanol cooled to -80 DEG C for 15 to 30 minutes So as to be instantaneously processed.
- the mold is put into a freeze dryer, stabilized in a supercooled state at 0 ° C to -5 ° C for 2 to 3 hours, and then treated at -30 ° C to -40 ° C for 3 to 4 hours .
- the CMCS solution is prepared by dissolving 3 to 5% CMCS in distilled water, adding 1 to 3% glycerin, and stirring the mixture for 2 hours or more.
- the CMCS solution prepared by stirring is filtered through a mesh screen to increase the purity, and is stored at 2 to 4 ° C to remove bubbles.
- the chitosan-based hemostatic member for cervical cancer according to the present invention has an effect of preventing the patient from being in danger due to excessive hemorrhage by allowing effective hemostasis against a specific lesion.
- the present invention is provided in a shape most suitable for a specific lesion, the present invention can be applied to a lesion immediately without a separate pretreatment, thereby providing convenience to a medical staff.
- the hemostatic member of the present invention can be provided with peripheral pressure units on the right and left sides of the hemostasis band, thereby achieving a more efficient hemostatic effect on the affected area.
- the hemostatic member of the present invention uses a thread including the X-ray sensitive material, even if the hemostatic member is not removed to the outside of the body due to a mistake, it is possible to easily grasp the position and take measures.
- FIG. 1 is a conceptual view of a hemostatic member based on chitosan for cervix according to a first preferred embodiment of the present invention.
- FIG. 2 is a conceptual view of a hemostatic member based on chitosan for cervix according to the second embodiment.
- FIG. 3 is a conceptual view of a hemostatic member based on chitosan for cervix according to the third embodiment.
- FIG. 4 is a conceptual view of a hemostatic member based on chitosan for cervix according to the fourth embodiment.
- FIG. 5 is a conceptual view of a hemostatic member according to a fifth embodiment
- FIG. 6 is a conceptual view of a hemostatic member according to the sixth embodiment.
- FIG. 7 is a conceptual view of a hemostatic member according to a seventh embodiment.
- FIG. 8 is a conceptual diagram according to an eighth embodiment
- Fig. 9 is a view showing an example of formation of a hemostatic bundle showing the process of making a hemostatic bundle using chitosan nonwoven fabric.
- FIG. 10 is a process chart of a method for manufacturing a chestnut-based hemostatic member for cervix.
- Fig. 11 is an exemplary view showing the use of the hemostatic member of the present invention.
- FIG. 2 is a conceptual view of a chitosan-based hemostatic member for cervix according to a second embodiment
- Fig. 3 is a schematic view of a chitosan-based hemostatic member for cervical chitosan according to a first preferred embodiment of the present invention
- 4 is a conceptual view of a chitosan-based hemostatic member for cervical cervix according to a fourth embodiment of the present invention
- FIG. 5 is a schematic view of a chitosan-
- FIG. 6 is a conceptual diagram of a hemostatic member according to a sixth embodiment
- FIG. 7 is a conceptual diagram of a hemostatic member according to a seventh embodiment
- FIG. 8 is a conceptual view according to the eighth embodiment
- FIG. 10 is a process chart of a method for manufacturing a hemostatic member based on chitosan for cervix
- FIG. 11 is a view showing a process for producing a hemostatic member using a chitosan nonwoven fabric. It shows an exemplary view to be.
- the chitosan-based hemostatic member (hereinafter, referred to as a hemostatic member) of the present invention is inserted into a cervical tissue test or a surgical site.
- the hemostatic member A is formed of a hemostatic sheath 200 using a chitosan nonwoven fabric 100, and is formed into a round shape by using a chitosan nonwoven fabric 100.
- the upper end is bundled with a thread 300 to have a stem 210 to collect the edges of the stem 100 and make it round as a ball.
- the thread 300 used to form the stem 210 is made of a thread containing an X-ray sensitive substance.
- the chitosan nonwoven fabric 100 is made of fibers containing chitosan and has a characteristic of excellent hemostatic action by chitosan components.
- the edges are gathered and the upper ends are bundled with the threads 300, thereby forming a round hemostatic wand 200.
- the chitosan nonwoven fabric 100 can be inserted into the affected part using the hemostatic wand 200 formed into a round shape and used as the hemostatic member A.
- the CMCS coating layer 400 may be formed on the outer surface of the hemostasis bundle 200 as shown in FIG.
- CMCS Carboxymethyl chitosan
- CMCS has better ability to absorb blood and is effective in hemostasis because it acts to coat the lesion.
- CMCS has the characteristics of good biocompatibility, non-toxicity, and good biodegradability.
- the CMCS coating layer 400 may be thinly formed on the outer surface of the hemostasis bundle 200. It is further preferable that the CMCS coating layer 400 be coupled so that the CMCS sponge 500 is wrapped around the CMCS coating layer 400.
- the CMCS sponge 500 has a considerable thickness. After the CMCS coating layer 400 is coated on the hemostasis bundle 200 in advance, the CMCS sponge 500 is formed, A CMCS sponge 500 having a uniform thickness can be formed while the CMCS coating layer 400 is not introduced into the inside of the CMCS coating layer 400.
- CMCS coating layer 400 or CMCS sponge 500 may be formed by using a CMCS solution so as to form a CMCS coating layer 400 on the hemostasis bundle 200.
- CMCS solution so as to form a CMCS coating layer 400 on the hemostasis bundle 200.
- CMCS coating layer 400 When the hemostasis bundle 200 is thinly formed, And then dried to form a thin CMCS coating layer 400.
- a hemostatic member may be formed so that the CMCS sponge 500 is directly wrapped around the outer surface of the hemostasis bundle 200.
- the thickness uniformity may be somewhat lowered, but the function as the hemostasis member A can be sufficiently performed.
- the thickness of the CMCS sponge 500 formed on the outer surface of the hemostasis bundle 200 or the CMCS coating layer 400 is in the range of about 2 to 10 mm.
- the CMCS sponge 500 has a sponge structure having a certain thickness and thus has an excellent blood absorption ability. When the blood is absorbed, the sponge structure becomes gelled and coats the affected part while coating the affected part.
- the CMCS sponge 500 in order for the CMCS sponge 500 to absorb an adequate amount of blood, it should have a thickness in the range of 2 to 10 mm. If the thickness is less than 2 mm, the blood absorbing ability is insufficient, and if the thickness is more than 10 mm, the size of the hemostat member A becomes excessively large and it may be difficult to apply the hemostatic member A to the affected part.
- the chitosan-based hemostatic member for cervical cervix of the present invention can be formed as shown in FIGS. 3 and 4.
- FIG. 3 The chitosan-based hemostatic member for cervical cervix of the present invention can be formed as shown in FIGS. 3 and 4.
- FIG. 3 The chitosan-based hemostatic member for cervical cervix of the present invention can be formed as shown in FIGS. 3 and 4.
- the hemostasis bundle 200 is formed by binding the stem 210 with the thread 300 so that the chitosan nonwoven fabric 100 has a round shape, And a thread 300 including an X-ray sensitive material may be connected to the peripheral pressing part 220.
- the peripheral pressing portion 220 connected to the hemostasis bundle 200 is formed by connecting a general nonwoven fabric or a chitosan nonwoven fabric in a straight line and the peripheral pressing portion 220 is inserted around the cervix to pressurize the inside for hemostasis So as to help the hemostatic effect.
- the thread 300 connected to the peripheral squeezing unit 220 is twisted from the inside of the hemostasis bundle 200 and is formed to extend while passing through the inside of the peripheral squeezing unit 220 one by one.
- the thread 300 connected to the peripheral pressing part 220 can be utilized for positioning of the hemostatic member A inserted into the body by the inclusion of the X-ray sensitive material, and after the sufficient hemostatic operation is performed, The hemostat member A can be easily removed by pulling the end of the thread 300.
- the hemostasis bundle 200 may be formed as a modified example in which the lower end is convexly protruded.
- the pressure level can be increased when the hemostasis bundle 200 is inserted into the affected area, thereby providing a better hemostatic effect.
- the shape modification of the hemostasis bundle 200 can be applied to all of the first to fourth embodiments mentioned above.
- FIG. 9 is a view illustrating a procedure of forming a hemostatic band using a chitosan nonwoven fabric
- FIG. 10 is a flowchart illustrating a method of manufacturing a hemostatic member according to an embodiment of the present invention.
- the method of manufacturing a hemostatic member according to the present invention includes a step of preparing a chitosan nonwoven fabric (S100) and a step of forming a hemostatic band (S200).
- the chitosan nonwoven fabric preparation step (S100) is to prepare a chitosan nonwoven fabric 100 made of chitosan fibers.
- a hemostatic wand forming step S200 for making the hemostatic wand 200 using the prepared chitosan nonwoven fabric 100 is performed.
- a plurality of chitosan nonwoven fabrics 100 are laminated and the edges are gathered to form a stem 210 at the upper end.
- the hemostasis bundle (200) is made by binding the stem (210) made round by using the thread (300).
- CMCS coating layer formation step S300 follows, followed by a CMCS sponge formation step S400.
- the hemostasis bundle 200 is immersed in the CMCS solution so that the CMCS coating layer 400 is formed on the hemostasis bundle 200 surface.
- the hemostasis bundle (200) is immersed in a prepared CMCS solution, then taken out and squeezed, followed by natural drying. If it is dried for about 16 hours, a thin CMCS coating layer 400 is formed on the surface of the hemostasis bundle 200.
- CMCS coating layer 400 is formed on the hemostasis bundle 200
- a CMCS sponge 500 covering the outer surface of the CMCS coating layer 400 is formed.
- the CMCS sponge 500 is formed to have a thicker thickness than the CMCS coating layer 400, and the CMCS solution is injected into a predetermined molding frame to fix it to have a round shape.
- the CMCS sponge formation step (S400) may further be subdivided into a hemostasis step (S410), an injection step (S420), a lyophilization step (S430), and a heat treatment step (S440).
- the hemostasis bundle 200 is placed in a predetermined forming mold to fix the hemostasis bundle (S410).
- the injection step S420 is to inject the CMCS solution into the mold.
- the CMCS solution fills the CMCS coating layer 400 and fills the mold cavity.
- the CMCS solution is injected into the mold, followed by a lyophilization step (S430).
- the molding frame is inserted into the freeze dryer, followed by rapid cooling and freeze drying to evaporate moisture,
- the CMCS sponge 500 integrated is formed.
- the lyophilization is carried out by raising the temperature from -40 ° C to 30 ° C in a vacuum state.
- the hemostasis bundle 200, the CMCS coating layer 400, and the CMCS sponge 500 are integrated to form one hemostatic member A.
- the preliminary freezing step (S425) is performed before the freeze-drying step (S430). That is, the preliminary freezing step is followed by the freeze-drying step.
- the temperature is rapidly lowered as much as possible to allow the maximum ice crystal generation zone of 0 to -5 DEG C to pass through within a short period of time to prevent the formation of ice during the freezing process, This is because it helps to make the voids (pores) constant when making the structure. In other words, by carrying out the preliminary freezing step (S425), it is possible to contribute to the improvement of the absorbing power.
- the mold is stabilized at 0 to -5 deg. C for 1 to 2 hours, and then immersed in ethanol cooled at an ultra-low temperature of -80 deg. C or lower to instantaneously freeze.
- it is immersed in ethanol cooled to -80 ⁇ or lower for about 15 minutes to 30 minutes to allow instantaneous freezing, and the ethanol immersion is preferably carried out in an ultra-low temperature freezer at 80 ⁇ .
- the preliminary freezing step (S425) may proceed to another condition as follows.
- Another type of preliminary freezing step (S425) is characterized by using a supercooling. That is, the mold is put into a freeze dryer, and after supercooling, rapid freezing (complete freezing in a few seconds) is performed so as to prevent ice from being formed in any process, and a sponge structure is formed through a heat treatment step (S440) This helps to ensure that the pores are formed uniformly.
- the preliminary freezing step (S425) it is possible to contribute to the improvement of the absorbing power.
- the mold is put into a freeze dryer, and is stabilized in a supercooled state at 0 ° C to -5 ° C for 2 to 3 hours, It is preferable to perform time processing.
- the heat treatment step (S440) is continued.
- the lyophilization body is heat-treated by heat, the sponge structure is activated by the crosslinking action to increase the blood absorption capacity.
- heat treatment is performed at a temperature of about 70 to 80 DEG C for 12 to 16 hours.
- the CMCS solution is prepared by dissolving 3 to 5% CMCS in distilled water, adding 1 to 3% glycerin and stirring for 2 hours or more.
- CMCS 3 to 5 g of CMCS powder is mixed with 100 ml of distilled water
- 1 to 3% of glycerin means 1 to 3 ml of glycerin mixed with 100 ml of distilled water.
- CMCS 3 to 5% of CMCS is dissolved in distilled water, 1 to 3% of glycerin is added, and stirring is performed for 2 hours or more to produce a CMCS solution. More preferably, the CMCS solution produced through stirring is filtered through a mesh net And high purity CMCS filtered by a mesh screen is manufactured by storing bubbles at 2 to 4 DEG C to remove bubbles.
- FIG. 11 is a diagram showing an actual use example of a chitosan-based hemostatic member for cervical part according to the present invention.
- the resection is performed in a sector shape as shown in FIG. 11, resulting in a lot of bleeding.
- the hemostatic member A of the present invention is used for hemostasis against the affected part and the hemostatic member A is inserted so as to block the hemostasis member 200 from the hemostasis member 200 to perform a hemostatic operation.
- the peripheral squeezing part 220 is pushed in the left and right side, the cut-out part is pushed inward and is further brought into close contact with the hemostasis bundle 200, so that hemostasis can be performed more easily.
- CMCS sponge 500 When the CMCS sponge 500 is formed on the hemostatic member A, blood is absorbed by the CMCS sponge 500, and the CMCS sponge 500 is gelled to coat the affected part, .
- the chitosan-based hemostatic member and method for manufacturing the same according to the present invention are suitable for a special purpose for hemostasis of the cervix.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Materials Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Mechanical Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (16)
- 자궁 조직 검사 또는 수술시 환부에 삽입되어 사용되는 지혈부재로서,지혈작용을 하는 키토산 부직포를 둥근 형상을 이루는 지혈뭉치로 형성하도록 하는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 제 1 항에 있어서,상기 지혈뭉치의 상단이 쓰레드(thread)로 묶여져 꼭지부를 형성하게 되는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 제 2항에 있어서,상기 쓰레드(thread)에 엑스레이(X-ray) 감응물질이 포함되도록 하는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 제 2 항에 있어서,상기 지혈뭉치의 외면에는 CMCS로 코팅된 CMCS 코팅층이 형성되는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 제 4 항에 있어서,상기 CMCS 코팅층 위로 CMCS 스펀지가 감싸도록 결합되는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 제 2 항에 있어서,상기 지혈뭉치의 외면에 CMCS 스펀지가 감싸도록 결합되는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 제 5 항 또는 제 6 항에 있어서,상기 CMCS 스펀지는 두께가 2 ~ 10mm 범위에 있는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 자궁 조직 검사 또는 수술시 환부에 삽입되어 사용되는 지혈부재로서,지혈작용을 하는 키토산 부직포를 둥근 형상을 이루도록 상단을 쓰레드(thread)로 묶어 꼭지부를 갖는 지혈뭉치가 형성되되,상기 꼭지부의 좌우 양측으로 일반 부직포 또는 키토산 부직포가 직선형태로 결합되어 주변압박부를 형성하게 되고, 주변압박부에 엑스레이(X-ray) 감응물질을 포함하는 쓰레드(thread)가 연결되어 연장되는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 제 8 항에 있어서,상기 주변압박부에 연결되는 쓰레드는 상기 지혈뭉치 내부로부터 한 가닥씩이 상기 주변압박부를 통과하여 연장되는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재.
- 키토산 섬유로 이루어지는 키토산 부직포를 준비하는 키토산 부직포 준비단계;복수 매의 키토산 부직포를 적층한 상태에서 가장자리를 모아서 꼭지부가 형성되게 엑스레이 감응물질을 포함하는 쓰레드로 묶어서 둥근 형상의 지혈뭉치를 만들도록 하는 지혈뭉치 성형단계;를 포함하는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재의 제조방법.
- 제 10 항에 있어서,상기 지혈뭉치 성형단계 다음으로,상기 지혈뭉치를 CMCS 솔루션에 침지되게 하여 상기 지혈뭉치 표면에 CMCS 코팅층이 형성되게 하는 CMCS 코팅층 형성단계;CMCS 코팅층 형성단계 후 CMCS 코팅층 외면으로 CMCS 솔루션으로 감싸 CMCS 스펀지가 형성되도록 하는 CMCS 스펀지 형성단계;를 포함하는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재의 제조방법.
- 제 11 항에 있어서,상기 CMCS 스펀지 형성단계는,성형틀에 상기 CMCS 코팅층이 형성된 지혈뭉치를 안착시키도록 하는 지혈뭉치 안착단계;상기 성형틀 내부로 상기 CMCS 솔루션을 주입하도록 하는 주입단계;상기 성형틀을 동결건조기에 투입하여 상기 CMCS 솔루션이 동결건조 되어 상기 지혈뭉치와 일체화되도록 하는 동결건조단계;동결건조로 성형된 동결건조체에 열을 가하여 열처리하도록 하는 열처리단계;를 포함하는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재의 제조방법.
- 제 12 항에 있어서,상기 동결건조단계에 앞서 예비동결단계가 수행되되,상기 예비동결단계는,상기 성형틀을 0~-5℃에서 1~2시간 안정화단계를 거친 후, -80℃ 이하로 냉각된 에탄올에 15분 내지 30분간 침지시켜 순간적으로 처리하도록 하는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재의 제조방법.
- 제 12 항에 있어서,상기 동결건조단계에 앞서 예비동결단계가 수행되되,상기 예비동결단계는,상기 성형틀을 동결건조기에 투입하여 0℃ ~ -5℃에서 2~3 시간 동안 과냉각 상태로 안정화 시킨 후 -30℃ ~ -40℃에서 3~4 시간 처리하도록 하는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재의 제조방법.
- 제 11 항 내지 제 14 항 중 어느 하나의 항에 있어서,상기 CMCS 솔루션은,3~5% CMCS를 증류수에 녹인 후, 1~3% 글리세린을 첨가하여 2시간 이상 교반하여 제조되는 것임을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재의 제조방법.
- 제 15 항에 있어서,교반을 통해 만들어진 CMCS 솔루션을 메쉬망을 통해 걸러서 순도를 높이도록 하며, 2~4℃에 보관하여 기포가 제거되도록 제조되는 것을 특징으로 하는 자궁 경부용 키토산 기반의 지혈부재의 제조방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/771,230 US10940230B2 (en) | 2017-09-29 | 2017-11-14 | Chitosan-based hemostatic member for cervix and method of manufacturing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0127526 | 2017-09-29 | ||
KR20170127526 | 2017-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019066131A1 true WO2019066131A1 (ko) | 2019-04-04 |
Family
ID=65902534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/012825 WO2019066131A1 (ko) | 2017-09-29 | 2017-11-14 | 자궁 경부용 키토산 기반의 지혈부재 및 이의 제조방법 |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR102169801B1 (ko) |
WO (1) | WO2019066131A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102475935B1 (ko) * | 2022-03-11 | 2022-12-08 | 구태훈 | 콜라겐과 카르복시메틸 셀룰로오스계 화합물 및 트롬빈을 포함하는 흡수성 지혈 패드, 및 그 제조방법 |
KR102475934B1 (ko) * | 2022-03-17 | 2022-12-08 | 구태훈 | 카복시메틸 키토산과 히알루론산 또는 그 유도체 및 트롬빈을 포함하는 흡수성 지혈 스펀지 패드, 및 그 제조방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040090033A (ko) * | 2003-04-16 | 2004-10-22 | 주식회사 효성 | 창상 피복재 및 조직공학 구조체용 중화 키토산 스폰지제조방법 및 이에 의해 제조된 중화 키토산 스폰지 |
US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
JP5075811B2 (ja) * | 2005-03-17 | 2012-11-21 | ランター(ユーケー) リミテッド | 抗菌創傷包帯の作製方法およびその使用 |
KR101517112B1 (ko) * | 2014-02-03 | 2015-05-04 | 순천향대학교 산학협력단 | 지혈용 패킹 주머니 |
CN106075552A (zh) * | 2016-06-30 | 2016-11-09 | 石家庄亿生堂医用品有限公司 | 一种医用止血海绵及其制备方法 |
KR101700107B1 (ko) * | 2016-03-15 | 2017-01-26 | 주식회사 엔도비전 | 키토산 기반의 지혈 드레싱재 및 그 제조방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9861517B2 (en) * | 2001-07-26 | 2018-01-09 | Cook Medical Technologies Llc | Vessel closure member, delivery apparatus, and method of inserting the member |
WO2003065877A2 (en) | 2002-02-04 | 2003-08-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
KR100554519B1 (ko) * | 2004-07-30 | 2006-03-03 | 주식회사 엠아이텍 | 혈관지혈구 |
EP2427157B1 (en) | 2009-05-04 | 2019-03-13 | Oregon Biomedical Engineering Institute, Inc. | Hemorrhage control devices and methods |
CN102525590A (zh) | 2010-12-10 | 2012-07-04 | 上海市第十人民医院 | 一种宫内压迫止血方法及装置 |
TWI547529B (zh) * | 2014-02-14 | 2016-09-01 | 瀚醫生技股份有限公司 | 形成雙層複合材料的方法與以此方法形成之雙層複合材料 |
-
2017
- 2017-11-14 WO PCT/KR2017/012825 patent/WO2019066131A1/ko active Application Filing
-
2018
- 2018-10-01 KR KR1020180117120A patent/KR102169801B1/ko active IP Right Grant
-
2020
- 2020-10-20 KR KR1020200135775A patent/KR102286622B1/ko active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
KR20040090033A (ko) * | 2003-04-16 | 2004-10-22 | 주식회사 효성 | 창상 피복재 및 조직공학 구조체용 중화 키토산 스폰지제조방법 및 이에 의해 제조된 중화 키토산 스폰지 |
JP5075811B2 (ja) * | 2005-03-17 | 2012-11-21 | ランター(ユーケー) リミテッド | 抗菌創傷包帯の作製方法およびその使用 |
KR101517112B1 (ko) * | 2014-02-03 | 2015-05-04 | 순천향대학교 산학협력단 | 지혈용 패킹 주머니 |
KR101700107B1 (ko) * | 2016-03-15 | 2017-01-26 | 주식회사 엔도비전 | 키토산 기반의 지혈 드레싱재 및 그 제조방법 |
CN106075552A (zh) * | 2016-06-30 | 2016-11-09 | 石家庄亿生堂医用品有限公司 | 一种医用止血海绵及其制备方法 |
Non-Patent Citations (1)
Title |
---|
CHENG, F.: "Antibacterial and hemostatic composite gauze of N,o-carboxymethyl chitosan/oxidized regenerated cellulose", RSC ADVANCES, vol. 6, no. 97, 22 September 2016 (2016-09-22), pages 94429 - 94436, XP055585589, ISSN: 2046-2069, DOI: 10.1039/C6RA15983D * |
Also Published As
Publication number | Publication date |
---|---|
KR102169801B1 (ko) | 2020-10-26 |
KR20190038462A (ko) | 2019-04-08 |
KR102286622B1 (ko) | 2021-08-05 |
KR20200122283A (ko) | 2020-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3111091C (en) | Composite dressings, manufacturing methods and applications thereof | |
JP4903308B2 (ja) | コラーゲン止血繊維 | |
US3988411A (en) | Spinning and shaping poly-(N-acetyl-D-glucosamine) | |
US20180236123A1 (en) | Hemostatic Composition and Hemostatic Device (Variants) | |
RU2498825C2 (ru) | Абсорбирующее медицинское тело, в частности, для удаления раневых жидкостей из полостей тела человека и животных и способ его изготовления | |
US4074366A (en) | Poly(N-acetyl-D-glucosamine) products | |
US20170252479A1 (en) | Biocompatible hemostatic product and preparation method thereof | |
US3989535A (en) | Solution of poly(N-acetyl-D-glucosamine) | |
KR102286622B1 (ko) | 자궁 경부용 지혈부재 | |
JP2021518803A (ja) | キトサン繊維性スポンジ構造の医療用ドレッシング材及びその製造方法 | |
WO1994017840A1 (en) | Pharmaceutical compositions comprising a spongy material consisting of ester derivatives of hyaluronic acid combined with other pharmacologically active substances | |
TWI263501B (en) | Sponge wound dressing made from chitin and alginate and method for forming the same | |
JP2015164526A (ja) | 二層複合材料を形成する方法、その方法で形成された二層複合材料、二層複合材料を含む生物医学機器 | |
BR112013020781B1 (pt) | Uso de um implante médico como barreira de adesão | |
CN107349457A (zh) | 一种胶原止血纤维的制备方法 | |
US10940230B2 (en) | Chitosan-based hemostatic member for cervix and method of manufacturing the same | |
WO2020145456A1 (ko) | 드레싱재가 포함된 자궁경부 유착 방지 장치 | |
WO2019022462A2 (ko) | 탐폰형 키토산 지혈재 | |
CN109276745A (zh) | 一种高湿强度的纤维素复合敷料及其制备方法 | |
CN104744723B (zh) | 壳聚糖医用材料及其制备方法和用途 | |
CN107715167A (zh) | 作为骨蜡替代物的壳聚糖基止血糊剂及制备方法 | |
CN104800880A (zh) | 一种含有止血消炎药物的可吸收海绵贴剂的制备技术 | |
TWI304845B (en) | Alginate/collagen composite fiber and method for producing the same | |
ITFI20070115A1 (it) | Tampone nasale. | |
CN108653797A (zh) | 一种鼻腔填塞用膨胀止血海绵及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17926729 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17926729 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 25.01.2021) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17926729 Country of ref document: EP Kind code of ref document: A1 |